Our synthetic neurotrophin mimetics are intended for treatment of corneal lesions, either spontaneous – the neurotrophic keratitis – or traumatic, or even iatrogenic, as is the case for laser treatment of miopy.

In this connection, on 16/12/2014, our lead compound was designated as orphan drug for the treatment of neurotrophic keratitis by EMA (European Medicines Agency).

Our compound also proved able to provide a marked neuroprotection to the retinal layer undergoing ischemia/reperfusion, the pathogenetic mechanisms leading to glaucoma.